Articles

From Research Grant to Acquisition: Does the IP Support the Deal?

Imagine buying a medical-device company whose financial projections depend on manufacturing overseas. The company has an exclusive university patent license, promising test results and a government-supported research history. During diligence, the buyer discovers that the license covers the first product but not the next indication, the testing agreement limits access to supporting data, and the manufacturing plan needs a separate legal review.

Nothing in this hypothetical means the technology is uninvestable. It means the buyer has been pricing a business plan before confirming the rights needed to carry it out.

Government grants and university partnerships can bring a company technology it could not otherwise afford to develop. The commercial challenge comes when research becomes a product, a financing or an acquisition. Investors need to know whether the rights assembled for the research will support what happens next.

That question reaches well beyond patents. It includes the process needed to manufacture reliably, the software that runs the product and the data a partner needs to evaluate it. A useful IP review follows those business dependencies, rather than treating public funding as a warning label attached to the entire company.

Follow the product back to the research

Start with what the company must be able to do after closing. Then work backward through the people, funding and agreements behind each essential asset. A patent schedule tells you what exists on paper. It does not explain whether a university owns a necessary improvement or whether a grant-funded development project carries continuing obligations.

Bayh-Dole supplies part of the answer for federally funded inventions. Its definition of a funding agreement reaches federal contracts, grants and cooperative agreements for research or development funded wholly or partly by the federal government, along with specified downstream arrangements. A "subject invention" is an invention of the contractor conceived or first actually reduced to practice in performing work under that agreement.[1]

The practical consequence is an asset-by-asset inquiry. Funding may reach the work through a university subaward rather than a direct agency payment. Conversely, a state incentive or access to subsidized equipment does not, by itself, make every company invention a subject invention. The award, work statement, incorporated clauses and development history matter. Later private investment should not be assumed to erase obligations already attached to an invention.

Ownership is a separate question. In Stanford v. Roche, the Supreme Court held that Bayh-Dole does not automatically vest title to federally funded inventions in federal contractors.[2] Someone still needs to establish how the company acquired its rights. Review executed assignments and competing institutional obligations, including those of faculty founders, students and consultants. A confidentiality agreement should not be mistaken for an invention assignment.

University policies also deserve a close reading. CU Boulder's policy, for example, identifies work responsibilities and substantial use of university resources as ownership grounds, while excluding resource use permitted under a separately executed facilities-use agreement from its definition of substantial use. That exclusion does not eliminate other ownership grounds. CU's system policy separately limits who may grant rights in university discoveries.[3] A founder's relationship with a professor cannot substitute for an agreement signed by someone authorized to bind the institution.

Understand what stays with the government

A government license is not government ownership. Under the standard federal patent-rights clause, the government retains a nonexclusive, nontransferable, irrevocable, paid-up license to practice a subject invention, or have it practiced, for or on behalf of the United States worldwide. This is not a general license for every competitor.[4]

That distinction helps keep diligence proportionate. A retained license may be an understood feature of the technology's history. Missing compliance records call for a different response. Review invention disclosures, election-of-title and patent-filing records, government-interest statements and required reporting against the actual award clause, including applicable employee and subcontract obligations. Certain failures can permit the agency to require conveyance of title. A missing document does not establish that ownership has already been forfeited, and a late filing cannot simply be assumed to cure the problem.[4]

March-in is different again. The statute permits an agency to require licenses on specified grounds and through prescribed procedures, including failures concerning practical application, health or safety needs, public-use requirements and domestic-manufacturing commitments. Public funding alone does not trigger march-in.[5]

Manufacturing can have a more immediate effect on the business plan. When a covered owner grants exclusive U.S. rights to use or sell a subject invention, section 204 generally requires the licensee to agree that products embodying it, or produced through its use, will be manufactured substantially in the United States. Agencies may grant individual waivers on specified grounds. This is not a blanket domestic-manufacturing rule for every publicly supported product.[6] If the margin forecast depends on overseas production, resolve applicability and any needed waiver before relying on that forecast.

Transaction structure matters too. Nonprofit assignments of U.S. rights in subject inventions face statutory approval requirements, with a qualifying invention-management exception.[4] Contractual assignment and change-of-control provisions need their own review. Federal-laboratory collaborations under a cooperative research and development agreement, or CRADA, operate under a separate statutory framework.[7] None of these questions is answered by a generic assurance that the company "owns its IP."

Buy the rights the business will actually use

An exclusive university license can be commercially strong and still narrower than the buyer expects. Its exclusivity may cover a particular field, territory or patent family. Research reservations, sponsor rights and exclusions for background technology or later improvements may leave important work outside the grant.

Return to the hypothetical device company. A license covering one clinical application may not support expansion into another. Permission to practice a patent may leave the manufacturing know-how with the university. These are reasons to examine the scope and negotiate missing rights, not reasons to discount every university license.

Read the agreement against ordinary operations: customer sublicenses, contract manufacturing, new product fields and the proposed acquisition. Understand milestones, termination rights and what survives termination. Joint ownership also needs attention: absent an agreement to the contrary, section 262 lets each joint patent owner practice the invention in the United States without the others' consent or an accounting.[8] Address commercialization and cooperation expressly. Separately, ownership of a patent does not establish freedom to operate the entire product without infringing others' rights.[9]

The most useful finding is therefore specific: the company needs a broader field, a consent or access to particular know-how. That gives the deal team something it can negotiate, price and resolve.

Protect the information behind the invention

For many research businesses, a patent is only part of what a buyer needs. Reproducible results may depend on datasets, source code and confidential processes. Those assets require their own rights analysis.

Where 2 C.F.R. § 200.315 applies, federal award rules separately reserve rights in covered copyrighted works and data, including specified reproduction, publication and use rights.[10] Read the applicable agency and award terms before promising a partner exclusive control. A patent license does not settle the data question.

Nor does marking a folder "confidential" establish a trade secret. Federal law requires qualifying economic value from secrecy and reasonable measures to preserve it.[11] Shared laboratories and collaborative repositories make access controls and confidentiality arrangements practical business concerns. Establish who can use essential information, what they may share and whether the company retains access when the collaboration ends.

Publication timing deserves the same attention. A dissertation, preprint or demonstration can disclose information before the patent team expects it. Public disclosure can affect patentability; U.S. statutory exceptions are no substitute for a filing strategy addressing the intended markets.[12] Seek publication review and a bounded filing delay where available, without assuming a university will accept an indefinite veto.

Public involvement does not make every submission public. Federal FOIA exempts qualifying trade secrets and confidential commercial or financial information, and CRADA law provides specific confidentiality protections.[7][13] State public-records rules and award-specific duties still require separate review.

Keep brands separate as well. A technology license does not necessarily authorize a university logo. Trademark assignments must include the associated goodwill; intent-to-use applications have additional statutory transfer limits, subject to a business-successor exception. Co-branding also calls for permission and appropriate quality control.[14] Patent diligence cannot supply those answers.

Colorado quantum shows why the agreements matter

Colorado's quantum-computing development brings these questions into focus. EDA reports approximately $41 million in Tech Hub grant funding awarded to the Elevate Quantum regional consortium. Its program supports open-access labs and fabrication facilities, workforce development and coordination.[15] The hub is a regional initiative, not a single laboratory or a grant to every participating company.

In Boulder, CU Boulder announced the January 2025 launch of a 13,000-square-foot quantum incubator with Colorado State University, Colorado School of Mines and Elevate Quantum. CU supplied leadership and staff resources. The incubator now advertises purpose-built laboratories and shared tools.[16] Those facts distinguish a launched, university-backed facility from proposed infrastructure, without establishing that every planned capability is operational.

Private commercialization is developing alongside it. Broomfield-headquartered Quantinuum announced an expanded, multiyear quantum-computing partnership with BMW in May 2026.[17] That company announcement is distinct from the hub award and incubator; it does not establish Quantinuum's receipt of hub funds or use of that facility.

The diligence lesson is the convergence. Public funding, university researchers, shared laboratories and private product development can bring several agreements to the same technical work. Equipment access may be governed by one contract, an inventor's obligations by another, and commercialization by a license. That creates more rights to trace, not automatic encumbrances. None of these announcements establishes an ownership defect at a named institution or company. Investors should connect the actual research to the actual agreements before drawing conclusions about exclusivity or control.

Resolve the gap before pricing around it

Sellers can make diligence faster by connecting awards and subawards to the inventions they supported, then supplying the assignments, licenses and compliance records that explain the company's position. Buyers should distinguish missing evidence from an actual restriction. Each demands a different solution.

If an essential license or consent is absent, consider making it a closing condition. Other uncertainties may warrant a price adjustment, a covenant to complete corrective work or a tailored indemnity. Assign responsibility for continuing grant compliance after closing. An indemnity cannot provide an absent license or restore secrecy to disclosed information.

Government and university support may be the reason the business exists. The aim is to preserve that value by making sure the rights acquired support the product, supply chain and growth plan the buyer is paying for.

Sources and authorities

1. 35 U.S.C. § 201(b), (c), (e), funding agreements, contractors and subject inventions.
2. Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc., 563 U.S. 776, 785-790 (U.S. Supreme Court, No. 09-1159, June 6, 2011), official opinion.
3. CU Boulder, Intellectual Property Policy, effective August 25, 2026, definitions; CU, APS 1013, section II.A. Accessed September 28, 2026.
4. 35 U.S.C. § 202; 37 C.F.R. § 401.14, especially (b)-(d), (f)-(h), (k). Actual award clauses and modifications require review.
5. 35 U.S.C. § 203, march-in grounds and procedures.
6. 35 U.S.C. § 204, manufacturing requirement and waivers.
7. 15 U.S.C. § 3710a, especially (b) and (c)(7), CRADA rights and confidentiality.
8. 35 U.S.C. § 262, joint patent owners.
9. USPTO, Managing a patent, patent rights are rights to exclude, not affirmative permission to practice. Accessed September 28, 2026.
10. 2 C.F.R. § 200.315, covered intangible property, copyright and data. Accessed September 28, 2026.
11. 18 U.S.C. § 1839(3)-(4), trade secrets and owners.
12. 35 U.S.C. § 102(a)-(b), novelty and statutory exceptions.
13. 5 U.S.C. § 552(b)(4), federal FOIA exemption, not state public-records law.
14. 15 U.S.C. § 1060(a), trademark assignments; 15 U.S.C. § 1055, controlled use.
15. EDA, Elevate Quantum Tech Hub award profile, undated; accessed September 28, 2026.
16. CU Boulder, New quantum incubator in Boulder to propel innovations for real-world impact, January 15, 2025; Colorado Quantum Incubator, Rentable lab space, undated; accessed September 28, 2026.
17. Quantinuum, Quantinuum and BMW Group expand landmark quantum computing collaboration with new multi-year partnership, May 5, 2026. Company announcement.

---

The information contained here is not intended to provide legal advice or opinion and should not be acted upon without consulting an attorney. Counsel should not be selected based on advertising materials, and we recommend that you conduct further investigation when seeking legal representation.